Global Gynaecology Drugs Market Report and Forecast 2024-2032

Global Gynaecology Drugs Market Outlook

The global gynaecology drugs market size was valued at USD 28.54 billion in 2023, driven by the rise in the geriatric population across the globe. The market size is anticipated to grow at a CAGR of 6.1% during the forecast period of 2024-2032 to achieve a value of USD 48.63 billion by 2032.

Gynaecology Drugs: Introduction

The medications that are used by women when they are pregnant are called as gynaecology drugs. The most used gynaecology drugs are analgesics, antimetics, antacids, antimicrobials, antiemetics, antacids, antihistamines, antimicrobials, diuretics, hypnotics, and tranquilizers, among others. These drugs are used to treat certain disorders that occur during pregnancy. The gynaecology drugs are used in the treatment of medical issues with female reproductive system and during pregnancy and childbirth. Hormonal and non-hormonal therapies are the major kind of treatments that are provided in gynaecology drugs. Hormonal therapy is also one of those as it blocks, reduces, or adds hormones that stop the growth of the cancer cells which require the growth of hormones.

Global Gynaecology Drugs Market Analysis

The increasing investments by the key players of the market in the development and research procedures to develop personalized cancer vaccines, including gynaecology cancers, is one of the key factors which is contributing to the gynaecology drugs market growth. Some of them have even reached the trial phases before their final launch in the market. Increased use of genetic sequencing and precision medicine has been going on to develop new drug therapies and cancer treatments to decrease the rate of Gynaecology cancer.

Gynaecology Drugs Market Segmentations

Market Breakup by Therapy Type

• Hormonal Therapy 

• Non-Hormonal Therapy

Market Breakup by Indication

• Gynaecology Cancers 

• Endometriosis 

• Female Infertility 

• Menopausal Disorder 

• Gynaecology Infections 

• Polycystic Ovary Syndrome (PCOS) 

• Contraception 

• Other Indication

Market by Route of Administration

• Oral 

• Parenteral 

• Intravaginal  

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy  

• Retail Pharmacy  

• Online Pharmacies  

• Others

Market Breakup by End User

• Hospitals 

• Specialty Clinics 

• Diagnostic Centers  

• Research Institute 

• Home Healthcare 

• Others

Market Breakup by Region

• North America  

• Europe 

• Asia Pacific 

• Latin America 

• Middle East and Africa

Global Gynaecology drugs Market Overview

The increasing number of women suffering from ovarian cancer is expected to favour the gynaecology drugs market expansion. The gynaecology drug market has been growing and is expected to grow in the coming years as well. Due to the increasing incidence of gynaecology cancer, the market is poised to witness robust growth in the coming years.

Gynaecology Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Eli Lilly and Company

• Pfizer, Inc.  

• Amgen Inc.  

• AstraZeneca  

• F. Hoffmann-La Roche Ltd.  

• Allergan Plc  

• Bayer AG Financial Analysis 

• AbbVie Inc.  

• Lupin Pharmaceuticals Inc.  

• Therapeutics MD Inc.  

• Ferring Holding S.A.  

• Teva Pharmaceutical Industries Limited  

• Addex Therapeutics Ltd.

Key Highlights of the Report